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See related research by Teng et al., http://www.breast-cancer-research.com/content/13/2/R35We read with interest the study by Teng and colleagues
reporting a high frequency (11.4 %) of epidermal growth
factor receptor (EGFR)-activating mutations in triple-
negative breast cancer (TNBC) in a Singapore cohort
[1]. In a separate study, EGFR-activating mutations were
detected in 7.7 % (1 out of 13) of Chinese basal-like
breast cancers [2]. Interestingly, this frequency ranged
from 0 to 3 % of other Asian and Caucasian patients [3, 4].
These results indicate that the frequency of these muta-
tions may vary according to geographic and ethnic differ-
ences, as reported in non-small cell lung cancer, and these
mutations appear to be limited mostly to Chinese patients
with TNBC. In this study, in-depth characterization of
these mutations in Chinese TNBC was attempted on retro-
spective archival tissues.
Fifty freshly frozen specimens of TNBC from patients
without neoadjuvant chemotherapy were randomly se-
lected from Zhejiang Cancer Hospital, China, from 2010
to 2011. The specimens were confirmed to be estrogen
receptor- and progesterone receptor-negative, and less
than 1 % of tumor cells showed positive nuclear staining
by an immunohistochemistry (IHC) assay. HER-2 nega-
tivity was defined as a score of 0 or 1+ by IHC assay or
a HER-2/chromosome 17 ratio of less than 2 and fewer
than 4 HER-2 copies per nucleus by a fluorescence in situ
hybridization assay. Written consent was obtained from all
participants. This study was approved by the Research and
Ethics Committee of Zhejiang Cancer Hospital.
Twenty-five EGFR-activating mutations (G719S, G719A,
G719C, S768I, L858R, and L861Q and 19 mutations of* Correspondence: wxiaojia@yahoo.com
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Mutation System (ARMS) assay by using an ADx EGFR29
Mutation Kit (Amoy Diagnostics, Xiamen, China). The
ARMS assay is able to detect mutations with allele fre-
quencies as low as 1 % [5]. Exons 18, 19, 20, and 21 were
amplified by polymerase chain reaction assay, and all frag-
ments were bidirectionally sequenced to screen for other
mutations.
None of the EGFR-activating mutations was found by
these two assays, but four single-nucleotide polymor-
phisms (SNPs) were identified by the sequencing assay
(Table 1).
In silico prediction was performed to investigate the
effect of the SNPs on gene splicing by using two pro-
grams: NNSplice 0.9 version (http://www.fruitfly.org/
seq_tools/splice.html) and Human Splicing Finder
(http://www.umd.be/HSF3/). All four SNPs, particularly
the c.2457G > A SNP, were predicted to alter splicing by
one or both programs.
In summary, none of the well-known EGFR-activating
mutations was identified in our cohort. This suggests
that TNBCs form a group of cancers with marked
heterogeneity. Targetable mutations may be present and
clinically helpful in only a limited number of Chinese
patients with TNBC.
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Table 1 Polymorphisms in exons 18, 19, 20, and 21 of EGFR in 50 triple-negative breast cancers





dbSNP NNSplice Human Splicing Finder





Intron 19 c.2283 + 103C > T - 0.1 (10) rs17290371 0.48:0.53 - Creation of an intronic ESE site
20 c.2361G > A Q787Q 0.18 (9) rs1050171 0:0.43 - Probably no impact on splicing
20 c.2457G > A V819V 0.04 (1) rs56183713 0.53:0 0.89:0.65 1. Creation of an exonic ESS site
2. Alteration of an exonic ESE site
Intron 20 c.2470-68C > A - 0.02 (1) rs530416576 - - Creation of an intronic ESE site
EGFR epidermal growth factor receptor, SNP single-nucleotide polymorphism, ESE exonic splicing enhancer, ESS exonic splicing silencer
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